首页> 外文期刊>Biological & pharmaceutical bulletin >Inhibition of benzo(a)pyrene induced lung adenoma by Panax ginseng extract, EFLA400, in Swiss albino mice
【24h】

Inhibition of benzo(a)pyrene induced lung adenoma by Panax ginseng extract, EFLA400, in Swiss albino mice

机译:人参提取物EFLA400对瑞士白化病小鼠抑制苯并(a)induced诱导的肺腺瘤

获取原文
获取原文并翻译 | 示例
           

摘要

In the present investigation the chemopreventive action of Panax ginseng extract, EFLA400, in Swiss albino mice has been evaluated. We used a 9-week medium term anticarcinogenicity test model of lung adenomas [Yuri et al.(1))]. Lung adenomas were induced by single subcutaneous injection in the subscapular region with 0.02 ml of benzo(a)pyrene (BP) (0.5 mg suspension in 1% aqueous gelatin) in newborn mice (less than 24 h old). Also chromosomal aberrations and micronuclei induction were evaluated in bone marrow cells. These genotoxicity endpoints were compared with adenoma incidence at the same dose levels of BP and EFLA400. The oral administration of EFLA400 (10 mg/kg body weight) showed significant reduction in number of adenomas and weight of the lungs induced by BP. A significant reduction (p < 0.001) in lung adenoma incidence in EFLA400-treated mice was observed as compared to the 68.3 +/- 2.96% lung adenoma incidence in BP-alone group. The inhibition rate was 72.05 +/- 1.36% in EFLA400-treated group with respect to the reference group (BP-alone group). However, tumor multiplicity was observed as 0.91 +/- 0.08 and 0.25 +/- 0.01 in BP alone and BP+EFLA400-treated groups respectively. In EFLA400-treated group significantly reduced frequencies of chromosomal aberrations and micronuclei induced by BP were observed. The results of the present investigation suggest the chemopreventive action and antimutagenic effect of EFLA400 in Swiss albino mice induced by BP in newborn mice.
机译:在本研究中,已评估了人参提取物EFLA400在瑞士白化病小鼠中的化学预防作用。我们使用了一个为期9周的肺腺瘤中期抗癌试验模型[Yuri et al。(1))。在新生小鼠(小于24 h)中,通过在肩sub下区域皮下注射0.02 ml苯并(a)py(BP)(0.5 mg在1%的明胶中的悬浮液),诱发肺腺瘤。还评估了骨髓细胞中的染色体畸变和微核诱导。将这些遗传毒性终点与在相同剂量水平的BP和EFLA400下的腺瘤发生率进行了比较。口服EFLA400(10 mg / kg体重)显示,BP引起的腺瘤数目和肺部重量明显减少。与仅BP组的68.3 +/- 2.96%的肺腺瘤发生率相比,在EFLA400处理的小鼠中肺腺瘤的发生率显着降低(p <0.001)。相对于参考组(仅BP组),EFLA400治疗组的抑制率为72.05 +/- 1.36%。然而,在单独的BP组和经BP + EFLA400治疗的组中,观察到的肿瘤多样性分别为0.91 +/- 0.08和0.25 +/- 0.01。在EFLA400治疗组中,观察到BP引起的染色体畸变和微核的频率显着降低。本研究的结果表明,EFLA400在BP诱导的新生小鼠瑞士白化病小鼠中具有化学预防作用和抗诱变作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号